HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

Huakang Biomedical Holdings Company Limited

Equities

8622

KYG4644W1069

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. Other stock markets 04:08:06 2024-04-30 am EDT			5-day change	1st Jan Change
0.098 ^HKD	-5.77%		-1.01%	-8.41%

Mar. 28	Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	CI

Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020

March 24, 2021 at 06:18 pm EDT

Huakang Biomedical Holdings Company Limited announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 21.967 million compared to CNY 25.471 million a year ago. Net loss was CNY 11.627 million compared to CNY 284,000 a year ago. Basic loss per share from continuing operations was CNY 0.0291 compared to CNY 0.0007 a year ago.

Latest news about Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	Mar. 25	CI
An unknown buyer acquired 15.59% stake in Huakang Biomedical Holdings Company Limited from Ever Charming Inc for HKD 3.2 million.	Jan. 24	CI
Huakang Biomedical Holdings Company Limited Announces Change of Address of Head Office, Effect from 18 December 2023	Dec. 15	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee	23-08-02	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021	22-03-04	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2021	21-10-28	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Huakang Biomedical Holdings Company Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021	21-07-29	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 30, 2021	21-05-11	CI
Huakang Biomedical Holdings Company Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended March 31, 2021	21-04-29	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-24	CI
Huakang Biomedical Holdings Company Limited Provides Earnings Guidance for the Year Ended December 31, 2020	21-03-05	CI
Huakang Biomedical Holdings Company Limited Announces Management Changes	20-12-16	CI
Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
Huakang Biomedical Holdings Company Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Nine Months Ended September 30, 2020	20-10-30	CI
Huakang Biomedical Holdings Company Limited Announces Management Changes	20-09-01	CI

Chart Huakang Biomedical Holdings Company Limited

Duration

Period

Chart Huakang Biomedical Holdings Company Limited

More charts

Company Profile

Huakang Biomedical Holdings Co Ltd is an investment holding company mainly engaged in the production and sales of in-vitro diagnostic reagents. The Company operates its business through two segments. The Biological Reagents and Auxiliary Reproductive Supplies and Equipment segment is engaged in the research and development, production, marketing and sales of in-vitro diagnostic reagents, including male infertility in vitro diagnostic reagents, parasite series detection reagents and Epstein-Barr (EB) virus detection reagents. The Segment is also engaged in the manufacture and sale of auxiliary reproductive supplies and devices. The Healthcare Products and Supplements segment is engaged in the sales of health products and supplements.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED	-8.41%	6.27M
BIOMÉRIEUX	-0.60%	12.63B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.67B
DIASORIN S.P.A.	+1.82%	5.42B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
LANTHEUS HOLDINGS, INC.	+7.32%	4.56B
10X GENOMICS, INC.	-47.68%	3.51B
ANDON HEALTH CO., LTD.	+6.42%	2.59B
VITROLIFE AB	-14.59%	2.05B
MYRIAD GENETICS, INC.	+2.25%	1.77B

Diagnostic & Testing Substances